A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Completed · Phase 2

Conditions studied: Head and Neck Cancer, Squamous Cell Carcinoma

In brief

The purpose of this study is to determine if the combination of two new drugs, cetuximab (Erbitux) and bevacizumab (Avastin) can increase the effectiveness of treatment for head and neck cancer. Cetuximab has recently been approved by the FDA for head and neck cancer (that is locally or regionally advanced) when used in combination with radiation therapy. Cetuximab is also approved by the FDA for the treatment of colorectal cancer

Key facts

Study ID

NCT00409565

Run by

National Cancer Institute (NCI)

People needed

48

Starts

2006-09-01

Expected to finish

2012-02-01

Last updated by the study team

2017-10-20

Who can join

Age: 18 and older, up to 98. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Michigan — Ann Arbor, Michigan, United States
• Case Western Reserve University — Cleveland, Ohio, United States
• UPMC / UPMC Cancer Centers — Pittsburgh, Pennsylvania, United States
• University of Texas MD Anderson — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.